Table 3.
Inter-tumoural PD-L1 heterogeneity: Comparison of PD-L1 TPS between primary NSCLC and matched nodal metastases, and comparison of PD-L1 TPS between matched nodal metastatic deposits.
| Primary vs. metastatic tumour PD-L1 TPS |
N1 vs N2 metastases PD-L1 TPS |
||||||
|---|---|---|---|---|---|---|---|
| TPS Change N (%) | Clinical Change N (%) | TPS Change N (%) | Clinical Change N (%) | ||||
| 0% | 50 (47) | No | 82 (77) | 0% | 29 (83) | No | 25 (81) |
| ≤10% | 31 (29) | Yes | 25 (23) | ≤10% | 3 (8.5) | Yes | 6 (19 |
| >10% | 26 (24) | ≥1% | 12 (11) | >10% | 3 (8.5) | ≥1% | 3 (10) |
| Total | 57 (53) | ≥25% | 3 (3) | Total | 6 (17) | ≥25% | 0 (0) |
| Range | 94 (1-95) | ≥50% | 10 (9) | Range | 90 (5-95) | ≥50% | 3 (10) |
PD-L1, Programmed death ligand 1; TPS, tumour proportion score; NSCLC, non-small cell lung cancer.